|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | PhaseI pharma- cokinetie and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand recep- tor显示文摘 | Tolcher AW Mita M Meropol NJ etal | 2007 | J Clin Oncol2007，25，： | 1 |
| 2 | Randomized phase II study of BR96- doxorubicin conjugate in patients with metastatic breast cancer显示文摘 | Tolcher A W | 1999 | J Clin Oncol1999，17，2： | 1 |
| 3 | A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense,G3139),an anti sense oligonucleotide to the bcl -2 mRNA,and of docetaxel in patients with hormone-refractory prostate cancer显示文摘 | KUHN J SCHWARTZ G | 2004 | Clin Cancer Res2004，10，15： | 1 |
| 4 | A phase I and pharmacokinetic study of CI-1033,a pan-ErbB tyrosine kinase inhibitor,given orally on days 1,8,and 15 every 28 days to patients with solid tumors显示文摘 | Garrison M A Tolcher A McCreery H | 2001 | Proc Am Soc Clin Oncol2001，20，： | 1 |
| 5 | Phase Ⅰ trial of the monoclonal antibody conjugate,BB-10901,for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors显示文摘 | Fossella FV Tolcher A Elliott M | 2002 | Proc Am Soc Clin Oncol2002，21，： | 1 |
| 6 | Novel therapeutic molecular targets for prostate cancer: the roTOR signaling pathway and epidermal growth factor receptor 显示文摘 | Tolcher AW | 2004 | J Urol2004，171，2： | 1 |
| 7 | Phase Ⅱ trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma显示文摘 | Fossella FV McCann J Tolcher A | 2005 | J Clin Oncol2005，23，16： | 1 |
| 8 | Phase I pharmacokinetic and biologic correlative study of mapatumumab,a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1显示文摘 | Tolcher AW Mita M Meropol NJ | 2007 | J Clin Oncol2007，25，11： | 1 |
| 9 | Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model显示文摘 | Gleave M Tolcher A Miyake H Nelson C Brown B Beraldi E | 1999 | Clin Cancer Res1999，5，： | 1 |
| 10 | Technology insight: cytotoxic drug immunoconjugates for cancer therapy 显示文摘 | Ricart AD Tolcher AW | 2007 | Nat Clin Pract Oncol2007，4，4： | 1 |
| 11 | Spontaneous rectus sheath hematoma pregnancy: case re- port and review of the literature显示文摘 | TOLCHER M C NITSCHE J F ARENDT K W | 2010 | Obstet Gynecol Surv2010，65，： | 1 |
| 12 | Reagent decontamination toeliminate false-positives in Escherichia coli qPCR显示文摘 | Silkie S S Tolcher M P Nelson K L | 2008 | J MicrobiolMethods2008，72，3： | 1 |
| 13 | Phase II trial of BB-10901(huN901-DM1)given weekly for four consecutive weeks every 6weeks in patients with relapsed SCLC and CD56-positive small cellcarcinoma显示文摘 | Fossella F McCann J Tolcher A | 2005 | J Clin Oncol2005，23，： | 1 |
| 14 | Phase I study of liposomal vincristine 显示文摘 | GELMON KA TOLCHER A DIAB AR | 1999 | J Clin Oncol1999，17，2： | 1 |
| 15 | A first-in-human phase Istudy of the CDK4/6 inhibitor, LY2835219, for patients with advancedcancer显示文摘 | Shapiro G Rosen L S Tolcher A W | 2013 | ASCO Meeting Abstracts2013，31，15： | 1 |
| 16 | Progression to androgen independence is delayed by adjuvant treatment with anti-sene bcl - 2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model显示文摘 | Gleave M Tolcher A Miyake H | 1999 | Clin Cancer Res1999，5，10： | 1 |
| 17 | Phase I , pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days 显示文摘 | TOLCHER A W FORERO L CELIO P | 2003 | Proc Am Soc Clin Oncol2003，22，9： | 1 |
| 18 | ONX 0912,a Novel Oral Proteasome Inhibitor (PI) ,In Patients (pts) With Advanced Re- fractory or Recurrent Solid Tumours : a Phase 1, O-pen - label, Dose Escalation Study显示文摘 | Papadopoulos K Mendelson D Tolcher AW et at | 2011 | European Journal of cancer2011，471，： | 1 |
| 19 | Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules 显示文摘 | Tolcher AW Gerson SL Denis L | 2003 | Br J Cancer2003，88，7： | 1 |
| 20 | Phase I , pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor l 显示文摘 | Tolcher AW Sarantopoulos J Patnaik A | 1997 | J Clin Oncol1997，27，34： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员